INFLAMMATION TARGETING PARTICLES
Opsonizable micro- or nanoparticles, that contain at least one active agent, such as an imaging or therapeutic agent; that have a positive surface charge and that do not contain on their surface targeting ligands, such as antibodies, peptides or aptamers, can be used to treating and/or monitoring a condition associated with an inflammation, such as a cytokine stimulated inflammation.
1 . A method for treating or monitoring a condition associated with an inflammation, comprising administering to a subject in need thereof a composition comprising opsonizable micro- or nanoparticles, that contain at least one active agent, wherein a surface of the micro or nanoparticles a) has a positive electrical charge and b) does not contain targeting ligands.
2 . The method of claim 1 , wherein the inflammation is a cytokine stimulated inflammation.
3 . The method of claim 1 , wherein the condition is a coronary artery disease.
4 . The method of claim 1 , wherein the condition is vasculitis.
5 . The method of claim 1 , wherein the condition is cancer.
6 . The method of claim 1 , wherein the administering is performed intravascularly.
7 . The method of claim 1 , wherein the subject is a human.
8 . The method of claim 1 , wherein the composition is a suspension comprising the opsonizable micro- or nanoparticles.
9 . The method of claim 1 , wherein the surface of the micro- or nanoparticles does not contain hydrophilic polymer chains.
10 . The method of claim 1 , wherein the micro- or nanoparticles are micro- or nanofabricated particles.
11 . The method of claim 1 , wherein the micro or nanoparticles are porous particles.
12 . The method of claim 11 , wherein the micro- or nanoparticles are nanoporous particles.
13 . The method of claim 11 , wherein the micro or nanoparticles are silicon porous particles.
14 . The method of claim 11 , wherein the micro- or nanoparticles are oxide porous particles.
15 . The method of claim 14 , wherein the micro- or nanoparticles are silicon oxide porous particles.
16 . The method of claim 1 , wherein the surface of the micro or nanoparticles is an aminomodified surface.
17 . The method of claim 16 , wherein the surface of the micro or nanoparticles is aminomodified by an aminosilane.
18 . The method of claim 1 , wherein said active agent is a therapeutic agent.
19 . The method of claim 1 , wherein said active agent is an imaging agent.
20 . The method of claim 1 , wherein said administering results in opsonization of said micro or nanoparticles and in targeting of cells associated with the inflammation by the opsonized micro- or nanoparticles.
21 . The method of claim 20 , wherein the cells associated with the inflammation are endothelial cells.
22 . The method of claim 20 , wherein the opsonized micro- or nanoparticles avoid uptake by macrophages of the subject.
23 . A composition comprising opsonizable micro- or nanoparticles, that contain at least one active agent, wherein a surface of the micro or nanoparticles a) has a positive electrical charge and b) does not contain targeting ligands.
24 . The composition of claim 23 , further comprising a solution and wherein the micro- or nanoparticles are suspended in the solution.
25 . The composition of claim 23 , wherein the surface of the micro- or nanoparticles does not contain hydrophilic polymer chains.
26 . The composition of claim 23 , wherein the micro- or nanoparticles are micro- or nanofabricated particles.
27 . The composition of claim 23 , wherein the micro or nanoparticles are porous particles.
28 . The composition of claim 27 , wherein the micro- or nanoparticles are nanoporous particles.
29 . The composition of claim 27 , wherein the micro or nanoparticles are silicon porous particles.
30 . The composition of claim 27 , wherein the micro- or nanoparticles are oxide porous particles.
31 . The composition of claim 30 , wherein the micro- or nanoparticles are silicon oxide porous particles.
32 . The composition of claim 23 , wherein the surface of the micro- or nanoparticles is an aminomodified surface.
33 . The composition of claim 32 , wherein the surface of the micro- or nanoparticles is modified by an aminosilane.
34 . The composition of claim 23 , wherein said active agent is a therapeutic agent.
35 . The composition of claim 23 , wherein said active agent is an imaging agent.
36 . A kit comprising the composition of claim 23 .
37 . A method for targeting inflamed cells in a subject,
comprising administering to the subject a composition comprising opsonizable micro- or nanoparticles, that contain at least one active agent, wherein a surface of the micro or nanoparticles a) has a positive electrical charge and b) does not contain targeting ligands.